Search PubMed⌕ Search

Biomedical subjects

G Thiringer

Publications and source records attributed to G Thiringer.

At least 37 records · Page 2Linked to original sources
PubMed1980

Metabolism of 14C-histamine given intrabronchially to asthmatic patients.

14C-histamine was administered intrabronchially to asthmatic patients and controls. The urinary excretion of total radioactivity, 14C-histamine and its radioactive metabolites was measured. It was found that the excretion of total radioactivity was complete within 24 h. The excretion rate was equal to that observed after intravenous injection of 14C-histamine, indicating a rapid penetration of the bronchial mucosa. However, the diuresis seemed to be of importance for the excretion rate. Histamine inactivation by methylation was more pronounced after intrabronchial than after intravenous administration.

Adult↗
PubMed1980

Epidemiological studies of lung cancer--influence of smoking habits.

It is important to evaluate epidemiological studies of lung cancer even when the smoking habits of the investigated groups are unknown. The increased risk for lung cancer in heavy smokers is known from other studies. Assuming a reference population consisting of 30% non-smokers, 25% ex-smokers, 40% moderate smokers and 5% non-smokers, it can be shown that a more than doubled incidence cannot be explained by differences in smoking habits.

Epidemiologic Methods↗
PubMed1980

Method of the cohort study--a practical example.

The method is demonstrated in connection with a study of lung cancer among metal-workers exposed to oil mist. As exposure to oil mist is uncommon and lung cancer is common, the cohort study is the method of choice. Estimation of exposure, problems of selection, calculation of person-years etc is discussed. There was no increased morbidity from lung cancer.

Adult↗
PubMed1979

Cefaclor therapy in acute exacerbations of chronic bronchitis.

Twenty-four patients with acute exacerbations of chronic bronchitis were treated with cefaclor at a dose of 500 mg every 8 hours for 10 days. Studies included volume, appearance and bacteriological examination of sputum, and haematological and virus serology tests. The response to therapy was judged on the reduction in sputum volume or the conversion of its character from purulent to mucoid. Nineteen of 24 patients improved and in 4 of 5 failures, positive serology for influenza virus was found. Growth of Pseudomonas occurred in one sputum. Minor side effects were seen in 3 patients, and no haematological or biochemical abnormalities were found.

Acute Disease↗
PubMed1977

Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline.

The increasing mortality in acute asthma noted during the sixties has been ascribed to resistance of the beta 2 receptors of the bronchi due to treatment with beta-stimulating drugs. This study questions that theory. Eight patients with reversible airways obstruction were studied. Treatment with oral terbutaline 5 mg 3 times a day was given for 1 yr. Thereafter, terbutaline as metered aerosol was added in the dose of 2 puffs (0.5 mg) 4 times a day for 4 days and 6 puffs (1.5 mg) 4 times a day for further 4 days. The responsiveness of the receptors of bronchi, heart, skeletal muscles, and peripheral vessels was tested before and after 1, 2, 3, 6, 9, and 12 mo of treatment with oral terbutaline and after the two 4-day periods with inhaled terbutaline. The receptors were tested by infusion of increasing doses of isoprenaline, so that dose-response curves for isoprenaline were recorded. No signs of resistance of the beta 2 receptors of the bronchi developed during the terbutaline treatment period. Thus no even spray in moderate overdose caused resistance. Within 1 mo of treatment with oral terbutaline, resistance developed to the tremorogenic effect of terbutaline. Six of the 8 patients showed no signs of development of resistance to the chronotropic effect of isoprenaline. No signs were found of resistance of the beta 2 receptors of peripheral blood vessels.

Adult↗
PubMed1977

Comparison of rimiterol and terbutaline, given by aerosol, in a long-term study.

In a double-blind long-term study, regular inhalations of a short-acting selective beta2-stimulator, rimiterol, was compared with a long-acting one, terbutaline. The trial comprised 60 patients with chronic obstructive lung disease, all patients were on a small dose of an oral beta2-stimulator. Both drugs were regularly given in aerosol form with a minimum dose of three inhalations three times daily. The main purpose was to study subjective and objective side effects. Haematological, hepatic and renal functions were screened for toxicity. Consumption of spray was recorded. No side effects occurred. There was no evidence of development of isoprenaline resistance. The consumption of spray was the same in both groups. In this study, regular inhalation treatment of rimiterol seemed to be as effective as terbutaline in long-term bronchodilator therapy.

Aerosols↗
PubMed1976

Comparison of infused and inhaled terbutaline in patients with asthma.

Skeletal muscle tremor is the most common side effect when giving the relatively selective beta2-adrenergic-stimulators. Tachycardia is a side effect which limits dosage in a few patients only. Dose-reponse relation was tested on ventilatory capacity, heart rate, blood pressure and skeletal muscle tremor after terbutaline was given intravenously and as an aerosol. Terbutaline infusions in doses exceeding the recommended therapeutic level did not produce maximal relaxation of the bronchial muscle in patients with endogenous asthma, but increased the heart rate by 25 beats per minute and more than doubled the tremor. The tachycardia is mainly due to peripheral vasodilation and reflexogenic heart stimulation. Terbutaline given by inhalation produced the same bronchial relaxation without any effect on heart rate, blood pressure of tremor, indicating a local effect. The acute margin of safety was notable; the increase of pulse after 63 inhalations of this long-acting substance being only 16 beats per minutes.

Adult↗
PubMed1975

Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.

The effects of propranolol (0.06 mg/kg i.v.), the selective beta1-receptor antagonist metoprolol (0.12 mg/kg i.v.) and a placebo on pulmonary function, heart rate and blood pressure have been compared in asthmatics. The interaction of these drugs with increasing doses of isoprenaline on the same variables was also studied. The two beta-blockers reduced resting heart rate to the same extent, indicating the same degree of blockade of cardiac beta-receptors. Both beta-blockers reduced the basal forced expiratory volume in one second (FEV1), and the effect tended to be more pronounced after propranolol. Isoprenaline caused a dose-dependent increase in FEV1 and vital capacity (VC). These effects were almost completely blocked by propranolol, whereas after metoprolol the changes approached that of the placebo. The isoprenaline-induced increase in heart rate and fall in diastolic blood pressure was also inhibited to a considerably greater extent by propranolol than by metoprolol. The results show a selectivity of metoprolol for so-called beta1-receptors and indicate that metoprolol may be used in asthmatics provided that it is combined with beta2-receptor-stimulating drugs.

Adult↗